Incidental Finding May Help Reata Produce First-In-Class Kidney Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The Texas-based private biotech hopes to develop new first-in-class anti-inflammatory drugs for chronic kidney disease and other disorders.